4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Basilea Pharmaceutica AG (BSLN) operates in the Biotechnology industry and is headquartered in Allschwil, Switzerland with about 200 employees. Its market capitalization is roughly CHF 813 million. In the fiscal year ended 2025-12-31, BSLN reported CHF 232M in revenue and CHF 40M in net income.
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
Interactive charts & full statements → Open the BSLN valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CHF 232M | CHF 208M | CHF 158M | CHF 148M | — |
| Gross Profit | CHF 193M | CHF 170M | CHF 131M | CHF 123M | — |
| Operating Income (EBIT) | CHF 52M | CHF 61M | CHF 19M | CHF 18M | — |
| Net Income | CHF 40M | CHF 78M | CHF 10M | CHF 12M | — |
CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CHF 282M | CHF 258M | CHF 173M | CHF 221M | — |
| Total Liabilities | CHF 154M | CHF 177M | CHF 183M | CHF 242M | — |
CHF; CHFM / CHFB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BSLN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms